Science & Technology
AGR2-superantigen vaccine conjugate for the treatment of pancreaticductal adenocarcinoma
Department of Health and Human Services — National Institutes of Health
Opportunity #: 4R44CA268138-02
Award Ceiling
$2.3M
Award Floor
$2.3M
Close Date
Jul 31, 2026
138 days leftTotal Funding
$2.3M
Expected Awards
1
Posted Date
Aug 1, 2023
Cost Sharing Required
No
Grants.gov ID
sbir-4R44CA268138-02
Description
SBIR Phase Phase II award: "AGR2-superantigen vaccine conjugate for the treatment of pancreaticductal adenocarcinoma" awarded to LEUKOGENE THERAPEUTICS INC in MOUNT PLEASANT, South Carolina. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $2,268,465. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.